Immunocore has raised more than $258m in an upsized offering and an additional $15m in a concurrent private placement.
Immunocore, a UK-based bispecific immunotherapy developer with roots at University of Oxford, issued approximately 9.94 million American Depositary Shares priced at $26 on Thursday to raise more than $258m in its IPO.
The company concurrently completed a $15m private placement, for total proceeds of more than $273m. It issued an additional 1.8 million shares and increased the price from $25 to $26 from its target a day earlier, and shares surged more than 66% to close at…
Thierry Heles
Thierry Heles is the editor of Global University Venturing, host of the Beyond the Breakthrough interview podcast and responsible for the monthly GUV Gazette (sign up here for free).
